ESR1 and neoplasm: The frequency of death based on clinical variables was found to be 26.37% for tumor size ≥ 5 centimeters, 19.22% for positive lymph node involvement, 18.79% for negative ER, 18.9% for negative PR, 18.4% for positive Her2neu receptor, 18.3% for positive P53 receptor, 16.06% for invasive ductal carcinoma pathology, 46.7% for stage IV and 17.01% for grade III.